All Stories

  1. Future fertility of patients with zero oocytes yield in their first IVF cycle attempt
  2. Is Day-4 morula biopsy a feasible alternative for preimplantation genetic testing?
  3. Can we predict oocyte maturation prior to denudation for intracytoplasmic sperm injection?
  4. Do poor-responder patients undergoing IVF benefit from splitting and increasing the daily gonadotropin dose?
  5. Does double trigger (GnRH-agonist + hCG) improve outcome in poor responders undergoing IVF-ET cycle? A pilot study
  6. Preimplantation embryos sex ratios in couples with four or more children of same sex, what should be expected from a preimplantation genetic diagnosis cycle?
  7. Biosimilar FSH preparations- are they identical twins or just siblings?
  8. The prostaglandin transporter (PGT) as a potential mediator of ovulation
  9. In vitro fertilization outcomes following placement of Essure® micro-inserts in patients with hydrosalpinges who previously failed IVF treatment – a multicenter study
  10. Transplantations of frozen thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria
  11. Does BPA alter steroid hormone synthesis in human granulosa cellsin vitro?
  12. Natural cycle frozen-thawed embryo transfer—can we improve cycle outcome?
  13. Reproductive Outcome Is Favorable After Laparoscopic Resection of Bladder Endometriosis
  14. Should pre-implantation genetic screening be implemented to routine clinical practice?
  15. FMR6 may play a role in the pathogenesis of fragile X-associated premature ovarian insufficiency
  16. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation
  17. Combination of ovarian tissue harvesting and immature oocyte collection for fertility preservation increases preservation yield
  18. The prostaglandin transporter (PGT): a novel indispensable mediator of ovulation
  19. Characterization of the human ovulatory non-coding transcriptome reveals mirnas as new regulators of the ovulatory cascade
  20. The capacity to induce generation of premeiotic and meiotic cells from biopsies without sperm from nonobstructive azoospermic and klinefelter syndrome patients were different under in vitro culture conditions
  21. Triggering final follicular maturation- hCG, GnRH-agonist or both, when and to whom?
  22. Interleukin-2 Production by Cultured Human Granulosa Cells
  23. Perinatal Outcome After Fetal Reduction From Twin to Singleton
  24. To pill or not to pill in GnRH antagonist cycles: what should be the appropriate wash-out period?
  25. Faculty of 1000 evaluation for Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized contro...
  26. A novel approach to normal responder patient with repeated implantation failures – a case report
  27. Perinatal outcome after fetal reduction from twin to singleton: to reduce or not to reduce?
  28. Comment on “The Role of Overweight and Obesity in In Vitro Fertilization Outcomes of Poor Ovarian Responders”
  29. Does bariatric surgery improve ovarian stimulation characteristics, oocyte yield, or embryo quality?
  30. Anti Müllerian Hormone (AMH) level and expression in mural and cumulus cells in relation to age
  31. Interleukin-2 and SOCS-1 proteins involvement in the pathophysiology of severe ovarian hyperstimulation syndrome-a preliminary proof of concept
  32. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes
  33. Chromosomal aneuploidies and DNA fragmentation of human spermatozoa from patients exposed to perfluorinated compounds
  34. Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for in vitro fertilization
  35. GnRH agonist versus GnRH antagonist in ovarian stimulation: has the ongoing debate resolved?
  36. The ‘immunologic theory’ of preeclampsia revisited: a lesson from donor oocyte gestations
  37. Ovarian performance, IVF results, pregnancies and live births indicate; fertility preservation using ovarian tissue harvesting and transplantation of thawed ovarian strips is effective
  38. IVF outcome in azoospermic cancer survivors
  39. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low rate of mature oocytes
  40. Elevated Levels of FMR1 mRNA in Granulosa Cells Are Associated with Low Ovarian Reserve in FMR1 Premutation Carriers
  41. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies
  42. Is severe OHSS associated with adverse pregnancy outcomes? Evidence from a case–control study
  43. Reactive oxygen species in follicular fluid may serve as biochemical markers to determine ovarian aging and follicular metabolic age
  44. Is the modified natural in vitro fertilization cycle justified in patients with “genuine” poor response to controlled ovarian hyperstimulation?
  45. Treating patients with “thin” endometrium – an ongoing challenge
  46. Misoprostol treatment for early pregnancy failure does not impair future fertility
  47. Pregnancy outcome in severe OHSS patients following ascitic/plerural fluid drainage
  48. 674: Is severe ovarian hyperstimulation syndrome associated with adverse pregnancy outcome? Evidence from a large case-control study
  49. Co-administration of GnRH-agonist and hCG for final oocyte maturation (double trigger) in patients with low number of oocytes retrieved per number of preovulatory follicles-a preliminary report
  50. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept
  51. Should zygote intrafallopian transfer be offered to all patients with unexplained repeated in-vitro fertilization cycle failures?
  52. Case Report: Delayed intra-abdominal bleeding following trans-vaginal ultrasonography guided oocyte retrieval for in vitro fertilization in patients at risk for thrombo-embolic events under anticoagulant therapy
  53. orvieto
  54. Alterations in thyroid function among the different polycystic ovary syndrome phenotypes
  55. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of elevated peak serum progesterone levels
  56. Early pregnancy
  57. Male and female fertility preservation
  58. Effects of treatment of ectopic pregnancy with methotrexate or salpingectomy in the subsequent IVF cycle
  59. Congenital malformations in infants conceived following assisted reproductive technology in comparison with spontaneously conceived infants
  60. GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate
  61. Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma
  62. Timing of human chorionic gonadotropin trigger, in patients undergoing controlled ovarian hyperstimulation for IVF, using the GnRH antagonist protocol
  63. The ultrashort flare GnRH-agonist/GnRH-antagonist protocol enables cycle programming and may overcome the “detrimental effect” of the oral contraceptive
  64. Testicular biopsies from non-obstructive azoospermic patients expressed different pre-meiotic cell markers
  65. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol
  66. Etiology of ovarian hyperstimulation syndrome
  67. Elimination of ovarian hyperstimulation syndrome
  68. Bleeding, severe pelvic infection, and ectopic pregnancy
  69. Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help?
  70. Faculty of 1000 evaluation for Contraindications to progestin-only oral contraceptive pills among reproductive-aged women.
  71. The role of CPK isoenzymes in predicting extrauterine early pregnancy
  72. Does day-3 LH/FSH ratio influencein vitrofertilization outcome in PCOS patients undergoing controlled ovarian hyperstimulation with different GnRH-analogue?
  73. Insight: Prolonged Vaginal Bleeding during Central Precocious Puberty Therapy with a Long-acting Gonadotropin-Releasing Hormone Agonist: A Proposed Mechanism and Management Plan
  74. Possible improvements in human ovarian grafting by various host and graft treatments
  75. Human sperm aneuploidy: FISH analysis in fertile and infertile men
  76. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen
  77. Metformin improves semen characteristics of oligo-terato-asthenozoospermic men with metabolic syndrome
  78. Does salpingectomy affect the ipsilateral ovarian response to gonadotropin during in vitro fertilization–embryo transfer cycles?
  79. Improving posttransplantation survival of human ovarian tissue by treating the host and graft
  80. The impact of environmental exposure to perfluorinated compounds on oocyte fertilization capacity
  81. The role of 3-dimensional ultrasound for the diagnosis of congenital uterine anomalies
  82. POSTER VIEWING SESSION - MALE AND FEMALE FERTILITY PRESERVATION
  83. A combined approach to patients with repeated IVF failures
  84. P24.18: Centralization and U turn of uterine arteries demonstrated by three dimensional power Doppler flow are new imaging signs for diagnosis of complete uterine inversion
  85. Human menopausal gonadotropin versus highly purified-hMG in controlled ovarian hyperstimulation forin-vitrofertilisation: does purity improve outcome?
  86. Infertility counseling for Orthodox Jewish couples
  87. Administration of clomiphene citrate in patients with polycystic ovary syndrome, without inducing withdrawal bleeding, achieves comparable treatment characteristics and outcome
  88. The association between follicular size on human chorionic gonadotropin day and pregnancy rate in clomiphene citrate treated polycystic ovary syndrome patients
  89. Cumulative clinical pregnancy rates after COH and IUI in subfertile couples
  90. Transplantation of frozen–thawed late-gestational-age human fetal ovaries into immunodeficient mice
  91. Influence of smoking on outcome of COH and IUI in subfertile couples
  92. Chronic ultra-low dose follicle-stimulating hormone regimen for patients with polycystic ovary syndrome: one click, one follicle, one pregnancy
  93. Follitropin-α (Gonal-F) versus follitropin-β (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?
  94. Do stimulation characteristics of the first in vitro fertilization cycle predict pregnancy in women of 40 years old and over?
  95. Is there a limit for the number of in vitro fertilization cycles for an individual patient?
  96. Ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist for patients with repeated IVF failures and poor embryo quality
  97. What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization?
  98. Repeated in vitro fertilization cycle attempts in patients undergoing controlled ovarian hyperstimulation with use of gonadotropin-releasing hormone antagonists
  99. GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a priori
  100. HMG improves IVF outcome in patients with high basal FSH/LH ratio: a preliminary study
  101. Ovarian stimulation in polycystic ovary syndrome patients: the role of body mass index
  102. Bleeding, severe pelvic infection and ectopic pregnancy
  103. The influence of body mass index on in vitro fertilization outcome
  104. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity
  105. Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH analogues?
  106. OP12.10: The role of 3-D ultrasound study of the endometrium in differentiating intrauterine versus extrauterine pregnancy
  107. The sperm chemoattractant secreted from human cumulus cells is progesterone
  108. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs
  109. Controlled ovarian hyperstimulation: are we monitoring the appropriate sex-steroid hormones?
  110. Reply: Appropriate methods to monitor controlled ovarian hyperstimulation?
  111. Does physicians' experience influence in vitro fertilization success in patients undergoing controlled ovarian hyperstimulation with GnRH antagonists?
  112. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in vitro fertilization outcome
  113. Selection of patients before and after anticancer treatment for ovarian cryopreservation
  114. Comparison of embryo quality between intracytoplasmic sperm injection and in vitro fertilization in sibling oocytes
  115. Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome
  116. OP15.06: The use of 3D ultrasound for diagnosis of unicornuate and didelphys uteri with twins gestation during first trimester of pregnancy
  117. Letter to the Editor
  118. Low endometrial volume may predict early pregnancy loss in women undergoing in vitro fertilization
  119. Use of three-dimensional ultrasound in evaluating the intrauterine position of a levonorgestrel-releasing intrauterine system
  120. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol
  121. A simplified approach to religious infertility
  122. Soluble CD40 Ligand Levels during Controlled Ovarian Hyperstimulation – A Possible Culprit of Systemic Inflammation
  123. Risk factors for failure to extend labor epidural analgesia to epidural anesthesia for Cesarean section
  124. P19.03: 3D study of uterine and endometrial parameters in uteri with Mullerian anomalies versus normal uteri
  125. Risk factors for failure to extend labor epidural analgesia to epidural anesthesia for Cesarean section*
  126. Müllerian anomalies, hearing loss, and connexin 26 mutations
  127. Serum anti-müllerian hormone levels in women with secondary amenorrhea
  128. Serum-Soluble CD40 Ligand in Normal Pregnancy and in Preeclampsia
  129. Does gravidity influence the success ofin vitrofertilization–embryo transfer cycles?
  130. Substituting HCG with GnRH agonist to trigger final follicular maturation – a retrospective comparison of three different ovarian stimulation protocols
  131. Hysteroscopy combined with hysterosalpingo contrast sonography (HyCoSy): A new modality for comprehensive evaluation of the female pelvic organs
  132. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation
  133. Use of various contraceptive methods and time of conception in a community-based population
  134. Anti-Mullerian Hormone in Premenopausal Women and After Spontaneous or Surgically Induced Menopause
  135. Ovarian androgens but not estrogens correlate with the degree of systemic inflammation observed during controlled ovarian hyperstimulation
  136. C-reactive protein levels in patients undergoing controlled ovarian hyperstimulation for IVF cycle
  137. Reply: Can we eliminate severe ovarian hyperstimulation syndrome?
  138. Replies: Can we eliminate severe ovarian hyperstimulation syndrome. Comments 1 and 2
  139. The influence of urinary versus recombinant gonadotropin on serum P-selectin levelsin vivo
  140. Immediate ambulation after embryo transfer: A prospective study
  141. Insulin autoantibodies in cord blood from neonates with and without a sibling with type 1 diabetes—prevalence and characterization
  142. Chapter-19 Ovarian Hyperstimulation Syndrome
  143. Serum androgen levels in patients undergoing controlled ovarian hyperstimulation forin vitrofertilization cycles
  144. Controlled ovarian hyperstimulation: Does prolonged stimulation justify cancellation ofin vitrofertilization cycles?
  145. Does intravaginal probiotic supplementation increase the pregnancy rate in IVF–embryo transfer cycles?
  146. Gestrinone in the treatment of uterine leiomyomata: Effects on uterine blood supply
  147. Effect of urinary versus recombinant follicle-stimulating hormone on platelet function and other hemostatic variables in controlled ovarian hyperstimulation
  148. Can we eliminate severe ovarian hyperstimulation syndrome?
  149. Can we eliminate severe ovarian hyperstimulation syndrome?
  150. M�llerian-inhibiting substance in women with polycystic ovary syndrome: Relationship with hormonal and metabolic characteristics
  151. Controlled Ovarian Hyperstimulation—An Inflammatory State
  152. Significance of Increased Endometrial Thickness in Assisted Reproduction Technology Treatments
  153. Serum P-selectin Level During Controlled Ovarian Hyperstimulation - a Preliminary Report
  154. Use of color Doppler sonography during follicular aspiration in patients undergoing in vitro fertilization may reduce the risk of blood vessel injury
  155. C-reactive protein levels in patients undergoing controlled ovarian hyperstimulation for IVF cycle
  156. Results ofin vitrofertilization cycles in women aged 43–45 years
  157. Effect of contaminated preprocessed semen on fertilization rate and embryo quality in assisted reproductive techniques
  158. Inclusion of standard and low-dose gonadotropin releasing hormone-analog (short protocol) in controlled ovarian hyperstimulation regimens in normogonadotropic patients aged 40-48 years who are undergoing in vitro fertilization
  159. Insulin autoantibodies in cord blood from neonates with and without a sibling with type 1 diabetes: prevalence and characteristics
  160. Attitudes of Israeli gynecologists regarding candidate screening and personal responsibility in assisted reproductive technologies versus adoption in Israel
  161. Interleukin-2 Production in Whole Blood Cell Cultures of Women Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproduction Technology Cycles
  162. Cobalamin (vitamin B12) metabolism during pregnancy
  163. Parameters affecting successful transplantation of frozen-thawed human fetal ovaries into immunodeficient mice
  164. Prediction of ovarian hyperstimulation syndrome: Challenging the estradiol mythos
  165. Polycystic ovary syndrome: a simplified approach based on the evolving set of symptoms
  166. The ‘virtual’ cervical internal os: diagnosis during the first trimester of pregnancy
  167. Chapter-57 Endometrial Preparation for Patients Undergoing Frozen-Thawed Embryo Transfer Cycles
  168. Nonobstructive Dilatation of the Fetal Bowel in Twin Gestations
  169. Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study
  170. Preliminary studies on apoptosis in human fetal ovaries
  171. Echogenic Bowel in Intrauterine Growth Restriction Fetuses
  172. Munchausen syndrome in obstetrics and gynecology
  173. Plasma Levels of Vitamin E in Pregnant Women prior to the Development of Preeclampsia and Other Hypertensive Complications
  174. Influence of hormone replacement therapy on postmenopausal pelvic organs
  175. Brachial plexus injury and obstetrical risk factors
  176. Prediction of Pregnancy Outcome in Subgroups of Women With Renal Disease
  177. Effect of Thrombophylaxis on Uterine and Fetal Circulation in Pregnant Women with a History of Pregnancy Complications
  178. Soluble L-selectin levels during controlled ovarian hyperstimulation
  179. Treatment of the twisted cystic ovary with normal blood flow by simple aspiration
  180. Influence of hormone replacement therapy on postmenopausal pelvic organs
  181. Soluble L-selectin levels during controlled ovarian hyperstimulation
  182. Double (consecutive) transfer of early embryos and blastocysts: aims and results
  183. Controlled Ovarian Hyperstimulation - A State of Endothelial Activation1
  184. F08Real-time intraoperative ultrasound guidance; the transrectal approach
  185. Polycystic ovary syndrome: a single gene mutation or an evolving set of symptoms
  186. Effect of Metformin on Insulin-Like Growth Factor (IGF) I and IGF-Binding Protein I in Polycystic Ovary Syndrome
  187. Pregnancy potential of embryos fromin vitrofertilization compared to intracytoplasmic sperm injection
  188. Natural-cyclein vitrofertilization in women aged over 44 years
  189. The rationale for requesting a second consecutive sperm ejaculate for assisted reproductive technology
  190. Gonadotropin stimulation following GnRH-a priming for poor responders inin vitrofertilization–embryo transfer programs
  191. Oral sildenafil may reverse secondary ejaculatory dysfunction during infertility treatment
  192. Simplifying amniocentesis in paraplegic women—the wheelchair tilting manoeuvre
  193. Controlled Ovarian Hyperstimulation: A State of Neutrophil Activation
  194. The role of purified follicle stimulating hormone therapy in the male partner before intracytoplasmic sperm injection
  195. Endometrial polyps during menopause, characterization and significance
  196. Albumin in the prevention of severe OHSS: Reply
  197. Fetal middle-cerebral and umbilical artery flow assessments after glucose challenge test
  198. Evaluation of the upper uterine cervix by the location of the vesicocervical fold of the urinary bladder to rule out cervical shortening during pregnancy with and without premature contractions
  199. Assessment of fetal cardiovascular function: ultrasound study of the fetal circulatory compartments
  200. Laparoscopic management of suspicious ovarian cysts in elderly, postmenopausal women
  201. Pregnancy and multiple sclerosis: a 2-year experience
  202. Does female age affect embryo morphology?
  203. Neonatal atrial flutter following fetal exposure to vibroacoustic stimulation
  204. Pregnancy Outcome in Patients with Insulin Dependent Diabetes Mellitus and Diabetic Nephropathy Treated with ACE Inhibitors before Pregnancy
  205. Standardin vitrofertilization or intracytoplasmic sperm injection in advanced female age – what may be expected?
  206. Endometrial polyps during menopause, characterization and significance
  207. Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome
  208. Pre-operative ultrasonographic evaluation of nongravid, enlarged uteri — correlation with bimanual examination
  209. Single intrauterine fetal death (fetus papyraceus) due to uterine trauma in a twin pregnancy
  210. Ovarian abscess after ovum retrieval for in-vitro fertilization
  211. Ovarian Hyperstimulation Syndrome: A New Insight Into an Old Enigma
  212. Abnormal Sonographic Endometrial Findings in Asymptomatic Postmenopausal Women
  213. Endometrial carcinoma in a post-menopausal woman with atrophic endometrium and intra-cavitary fluid: A case report
  214. Twin gestation: Is there a correlation between the location of the gestational sacs at the beginning of pregnancy, and the order of delivery
  215. Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist
  216. Asymptomatic postmenopausal intrauterine fluid accumulation; characterization and significance
  217. Flexible starting schedule for oral contraception: effect on the incidence of breakthrough bleeding and compliance
  218. The impact of intrauterine contraceptive devices on cytological findings from routine Pap smear testing
  219. Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist
  220. A new concept of cotreatment with human growth hormone and menotropins in ovulation induction protocols
  221. Morphology and clinical outcomes of embryos after in vitro fertilization are superior to those after intracytoplasmic sperm injection
  222. Gestational diabetes and preterm labour: is glycaemic control a contributing factor?
  223. CAUTION: PRENATAL CLUBFOOT CAN BE BOTH A TRANSIENT AND A LATE-ONSET PHENOMENON
  224. CAUTION: PRENATAL CLUBFOOT CAN BE BOTH A TRANSIENT AND A LATE‐ONSET PHENOMENON
  225. Torsion of a fallopian tube following Pomeroy tubal ligation: a rare case report and review of the literature
  226. Non-response to ovarian stimulation in normogonadotrophic, normogonadal women: a clinical sign of impending onset of ovarian failure pre- empting the rise in basal follicle stimulating hormone levels
  227. P-272 Fibrin sealant (FS) improves pregnancy rates in the elderly in-vitro fertilization (IVF) population, and maintains them within the more youthful range
  228. P-15.
  229. P-16.
  230. Ovarian cysts and cyclic hormone replacement therapy: is there an association?
  231. The residual ovary syndrome: a 20-year experience
  232. Uterine activity after betamethasone administration for the enhancement of fetal lung maturation
  233. Severe ovarian hyperstimulation syndrome despite low plasma oestrogen concentrations in a hypogonadotrophic, hypogonadal patient
  234. The impact of woman's age and sperm parameters on fertilization rates in IVF cycles
  235. Laparoscopic myomectomy today: The controversy of laparoscopic myomectomy
  236. Serum levels of insulin-like growth factor-1, IGF binding protein-1 and insulin and the response to human menopausal gonadotrophins in women with polycystic ovary syndrome
  237. Prophylactic intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome
  238. A delayed starting schedule of oral contraception: The effect on the incidence of breakthrough bleeding and compliance in women
  239. Etiology of ovarian hyperstimulation syndrome?
  240. A severe case of ovarian hyperstimulation syndrome despite the prophylactic administration of intravenous albumin
  241. The role of the immune system in severe ovarian hyperstimulation syndrome
  242. Polycystic ovary syndrome patients as oocyte donors: the effect of ovarian stimulation protocol on the implantation rate of the recipient
  243. The role of patient mobilization after embryo transfer in in vitro fertilization programs
  244. Interleukin-2 and ovarian hyperstimulation syndrome: a pilot study
  245. Recurrent spontaneous ovarian hyperstimulation syndrome associated with polycystic ovary syndrome
  246. The role of cytokines in early detection of preeclampsia
  247. Low-Back Pain of Pregnancy
  248. The role of intrapartum vibroacoustic stimulation in the prediction of neonatal myasthenia gravis
  249. Low-back pain of pregnancy
  250. The poor-responder patient in an in vitro fertilization-embryo transfer (IVF-ET) program
  251. Cytokines - Involvement in reproduction
  252. The possible role of intravenous immunoglobulin in preventing pre-eclampsia
  253. Cytokines—involvement in reproduction
  254. Bone density, mineral content, and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine
  255. Intravenous immunoglobulin treatment for recurrent abortions caused by antiphospholipid antibodies
  256. Intravenous immunoglobulin treatment of recurrent pregnancy loss and antiphospholipid antibodies
  257. Effect of Smoking on Concentration, Motility and Zona-Free Hamster Test on Human Sperm
  258. Faculty of 1000 evaluation for Postmenopausal skin and estrogen.
  259. Faculty of 1000 evaluation for Gonadotrophins for idiopathic male factor subfertility.
  260. Faculty of 1000 evaluation for In vitro fertilization with single euploid blastocyst transfer: a randomized controlled trial.
  261. Faculty of 1000 evaluation for Cumulative birth rates with linked assisted reproductive technology cycles.
  262. Faculty of 1000 evaluation for Variability of Semen Parameters Over Time in Placebo-Treated Men.
  263. Faculty of 1000 evaluation for Intra-uterine insemination for unexplained subfertility.
  264. Faculty of 1000 evaluation for Klinefelter syndrome: an argument for early aggressive hormonal and fertility management.
  265. Faculty of 1000 evaluation for Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review.
  266. Faculty of 1000 evaluation for Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study.
  267. Faculty of 1000 evaluation for Ovarian responsiveness in women receiving fertility treatment after methotrexate for ectopic pregnancy: a systematic review and meta-analysis.
  268. Faculty of 1000 evaluation for GnRH agonist and GnRH antagonist protocols: comparison of outcomes among good-prognosis patients using national surveillance data V.
  269. Faculty of 1000 evaluation for Age-specific probability of live birth with oocyte cryopreservation: an individual patient data meta-analysis.
  270. Faculty of 1000 evaluation for Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
  271. Faculty of 1000 evaluation for Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol.
  272. Faculty of 1000 evaluation for In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction.
  273. Faculty of 1000 evaluation for Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
  274. Faculty of 1000 evaluation for A randomized clinical trial to evaluate the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) in embryo culture medium for in vitro fertilization.
  275. Faculty of 1000 evaluation for Does intracytoplasmic morphologically selected sperm injection improve embryo development? A randomized sibling-oocyte study.
  276. Faculty of 1000 evaluation for In vitro maturation or in vitro fertilization for women with polycystic ovaries? A case-control study of 194 treatment cycles.
  277. Faculty of 1000 evaluation for Synchronization of ovarian stimulation with follicle wave emergence in patients undergoing in vitro fertilization with a prior suboptimal response: a randomized, controlled trial.
  278. Faculty of 1000 evaluation for The effect of sperm DNA fragmentation on miscarriage rates: a systematic review and meta-analysis.
  279. Faculty of 1000 evaluation for Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?
  280. Faculty of 1000 evaluation for Calcium infusion for the prevention of ovarian hyperstimulation syndrome: a double-blind randomized controlled trial.
  281. Faculty of 1000 evaluation for Effect of oxygen concentration on human embryo development evaluated by time-lapse monitoring.
  282. Faculty of 1000 evaluation for Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
  283. Faculty of 1000 evaluation for GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
  284. Faculty of 1000 evaluation for Low dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-analysis of the literature.
  285. Faculty of 1000 evaluation for Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel.
  286. Faculty of 1000 evaluation for Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilization implantation and delivery rates: a randomized controlled trial.
  287. Faculty of 1000 evaluation for Intrauterine exposure to mild analgesics during pregnancy and the occurrence of cryptorchidism and hypospadia in the offspring: the Generation R Study.
  288. Faculty of 1000 evaluation for The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis.
  289. Faculty of 1000 evaluation for High singleton live birth rate confirmed after ovulation induction in women with anovulatory polycystic ovary syndrome: validation of a prediction model for clinical practice.
  290. Faculty of 1000 evaluation for No evidence that assisted reproduction increases the risk of thrombosis: a Danish National cohort study.
  291. Faculty of 1000 evaluation for The duration of pre-ovulatory serum progesterone elevation before hCG administration affects the outcome of IVF/ICSI cycles.
  292. Faculty of 1000 evaluation for The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: A prospective randomized controlled study.
  293. Faculty of 1000 evaluation for A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders.
  294. Faculty of 1000 evaluation for Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis.
  295. Faculty of 1000 evaluation for A randomized controlled, non-inferiority trial of modified natural versus artificial cycle for cryo-thawed embryo transfer.
  296. Faculty of 1000 evaluation for A randomized clinical trial of endometrial perfusion with granulocyte colony-stimulating factor in in vitro fertilization cycles: impact on endometrial thickness and clinical pregnancy rates.
  297. Faculty of 1000 evaluation for A large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagoni...
  298. Faculty of 1000 evaluation for Use of hyaluronan in the selection of sperm for intracytoplasmic sperm injection (ICSI): significant improvement in clinical outcomes--multicenter, double-blinded and randomized controlled trial.
  299. Faculty of 1000 evaluation for Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
  300. Faculty of 1000 evaluation for Morphologic abnormalities in 2-year-old children born after in vitro fertilization/intracytoplasmic sperm injection with preimplantation genetic screening: follow-up of a randomized controlled trial.
  301. Faculty of 1000 evaluation for Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial.
  302. Faculty of 1000 evaluation for Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis.